Document Type : Original Research


1 Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

2 Department of Pathology Anatomy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

3 Division of Oncology, Department of Surgery, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia



Background & Objective: Breast cancer recurrence after surgery was a sign that the progress of the disease was continuing. Early detection of breast cancer patients who are at risk requires  development of a marker. Alfa smooth muscle actin (α-SMA) plays a role in the local recurrence process of invasive ductal carcinoma (IDC). Currently, existing tumor markers are used to predict the prognosis of breast cancer in general, not the early stages. Therefore, it was thought that finding α-SMA expression might predict early recurrence in early-stage IDC more accurately than others. This study investigated the potential role of α-SMA expression as a predictor of early recurrence in early-stage IDC and its relationship to clinicopathological factors.
Methods: The study design was cross-sectional, with data obtained from the medical records of Dr. Koesnadi, General Hospital, Bondowoso, Indonesia. Bivariate and multivariate analysis was performed to analyze data.
Results: We included 50 subjects divided into the local recurrence group (n=25) and the non-local recurrence group (n=25). We found a statistically significant correlation between the incidence of local recurrence in early-stage IDC and the high expression of α-SMA (odd ratio [OR]=23.22, 95% confidence interval [CI]=5.101-105.7, P=0.001). Clinicopathological variables and α-SMA expression did not have a significant correlation.
Conclusion: In early-stage IDC, α-SMA expression had the potential to predict and could be an independent prognostic factor for early recurrence.


Main Subjects

  1. Ren' R, Mulder RL, Hudson MM, Bhatia S, Landier W, Levitt ; Gill, et al. Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. J Clin Oncol. 2020;38:4194-207. [DOI:10.1200/JCO.20.00562] [PMID]
  2. Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028-37. [DOI:10.1200/JCO.2005.04.3273] [PMID]
  3. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84. [DOI:10.1016/S0140-6736(11)60993-8] [PMID]
  4. Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: Results from five National Surgical Adjuvant Breast and Bowel. J Clin Oncol. 2006;24(24):3927-32. [DOI:10.1200/JCO.2006.06.9054] [PMID]
  5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI:10.3322/caac.21660] [PMID]
  6. Cancer Today [Internet]. 2018 [cited 2020 Nov 11]. Available from:
  7. Panigoro SonarS, Karsono R, Sari L. E-cadherin and Vimentin as Predictors of Resistance to Preoperative Systemic Therapy in Patients with Advanced Breast Cancer. J Kedokteran Indonesia. 2017;4(3):27-30. [DOI:10.23886/ejki.4.7109.149-55]
  8. Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23(12):620-33. [DOI:10.1016/j.tcb.2013.07.006] [PMID]
  9. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907-20. [DOI:10.1189/jlb.71.6.907]
  10. Mangia A, Malfettone A, Rossi R, Paradiso A, Ranieri G, Simone G, et al. Tissue remodelling in breast cancer: human mast cell tryptase as an initiator of myofibroblast differentiation. Histopathology. 2011;58(7):1096. [DOI:10.1111/j.1365-2559.2011.03842.x] [PMID]
  11. Gabbiani G. Evolution and clinical implications of the myofibroblast concept. Cardiovasc Res. 1998;38(3):545-8. [DOI:10.1016/S0008-6363(98)00065-0] [PMID]
  12. Fernández-Nogueira P, Fuster G, Gutierrez-Uzquiza Á, Gascón P, Carbó N, Bragado P, et al. Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis. Cacers. 2021. [DOI:10.3390/cancers]
  13. Tang X, Tu G, Yang G, Wang X, Kang L, Yang L, et al. Autocrine TGF-β1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status to fuel breast cancer cell proliferation. Cancer Lett. 2019;28(452):79-89. [DOI:10.1016/j.canlet.2019.02.044] [PMID]
  14. Bill R, Christofori G. The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett. 2015;589(14):1577-87. [DOI:10.1016/j.febslet.2015.05.002] [PMID]
  15. Beerling E, Seinstra D, de Wit E, Kester L, van der Velden D, Maynard C, et al. Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity. Cell Rep. 2016;14(10):2281-8. [DOI:10.1016/j.celrep.2016.02.034] [PMID]
  16. Panawala L. Difference Between Epithelial and Mesenchymal Cells Main Difference - Epithelial vs Mesenchymal Cells. 2018;(June 2017).
  17. Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical statistics. Bone Marrow Transplant. 2013;48(3):452-8. [DOI:10.1038/bmt.2012.244] [PMID]
  18. Rui Z. ReproducibilityoftheNotingham modificationoftheScarf- Bloom-Richardsonhistologicalgradingsystem and the com plem entary value ofK i一67 to this system. Chin Med J. 2011;123(15):35-44.
  19. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease. J Am Coll Surg. 2009;208(3):341-7. [DOI:10.1016/j.jamcollsurg.2008.12.001] [PMID]
  20. Galea MH, Blarney RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207-19. [DOI:10.1007/BF01840834] [PMID]
  21. Shen ZZ. Relation of tumor size, lymph node status and prognosis in breast cancer. Chin J Surg. 1991 Sep;29(9):554-89.
  22. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853 - A study by the EORTC breast cancer cooperative group an. J Clin Oncol. 2006;24(21):3381-7. [DOI:10.1200/JCO.2006.06.1366] [PMID]
  23. Auayporn M. Exploring Breast Cancer Data to Find the Risk Factors for Distant Metastasis: Register Data, The National Cancer Institute of Thailand Montida Auayporn Piangchan Rojanavipart Chukiat Viwatwongkasem Arkom Chaiwerawattana Kitiphong Hancharoen. J Public Health. 2009;39.
  24. Vicini FA, Kestin L, Huang R, Martinez A. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer. 2003;97(4):910-9. [DOI:10.1002/cncr.11143] [PMID]
  25. Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD, Li SD. Docetaxel conjugate nanoparticles that target a-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res. 2013;73(15):4862-71. [DOI:10.1158/0008-5472.CAN-13-0062] [PMID]
  26. Singh A, Settleman JE. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741-51. [DOI:10.1038/onc.2010.215] [PMID]
  27. Paulsson J, Ryd L, Strell C, Frings O, Tobin NP, Fornander T, et al. High expression of stromal PDGFR b is associated with reduced benefit of tamoxifen in breast cancer. J Pathol Clin Res J. 2017;3:38-43. [DOI:10.1002/cjp2.56] [PMID]
  28. Lazard D, Sastre X, Frid MG, Glukhova MA, Thiery JP, Koteliansky V. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proceedings of the National Academy of Sciences. 1993;90(3):999-1003. [DOI:10.1073/pnas.90.3.999] [PMID]
  29. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD. EMT tumorigenesis in the mouse mammary gland. Lab Invest. 2007;87(12):1218-26. [DOI:10.1038/labinvest.3700683] [PMID]
  30. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007;9(12):1392-400. [DOI:10.1038/ncb1658] [PMID]
  31. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335-48. [DOI:10.1016/j.cell.2005.02.034] [PMID]
  32. Yang K, Zhang J, Bao C. Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis. BMC Cancer. 2021;21(1). [DOI:10.1186/s12885-021-08669-9] [PMID]
  33. Zhan S, Liu Z, Zhang M, Guo T, Quan Q, Huang L, et al. Overexpression of B7-H3 in α-SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas. Front Oncol. 2020;9. [DOI:10.3389/fonc.2019.01466] [PMID]
  34. Qiao Y, Zhang C, Li A, Wang D, Luo Z, Ping Y, et al. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. Oncogene. 2018;37(7):873-83. [DOI:10.1038/onc.2017.387] [PMID]
  35. Amornsupak K, Insawang T, Thuwajit P, O-Charoenrat P, Eccles SA, Thuwajit C. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer. 2014;14(1). [DOI:10.1186/1471-2407-14-955] [PMID]
  36. Ojha U, Goel S. A study on prediction of breast cancer recurrence using data mining techniques. In: 2017 7th International Conference on Cloud Computing, Data Science & Engineering - Confluence. 2017. p. 527-30. [DOI:10.1109/CONFLUENCE.2017.7943207]
  37. Zain ZM, Alshenaifi M, Aljaloud A, Albednah T, Alghanim R, Alqifari A, et al. Predicting breast cancer recurrence using principal component analysis as feature extraction: An unbiased comparative analysis. Int J Adv Intell Informatics. 2020;6(3):313-27. [DOI:10.26555/ijain.v6i3.462]